Zanubrutinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Zanubrutinib
Accession Number
DB15035
Type
Small Molecule
Groups
Investigational
Description

Zanubrutinib is under investigation in clinical trial NCT02795182 (BGB-3111 in Combination With BGB-A317 in Subjects With B-cell Malignancies).

Structure
Thumb
Synonyms
Not Available
External IDs
BGB-3111
Categories
Not Available
UNII
AG9MHG098Z
CAS number
1691249-45-2
Weight
Average: 471.561
Monoisotopic: 471.227039814
Chemical Formula
C27H29N5O3
InChI Key
RNOAOAWBMHREKO-QFIPXVFZSA-N
InChI
InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
IUPAC Name
SMILES
NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
64835237
BindingDB
250082
ChEMBL
CHEMBL3936761

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers: Asian, Non-Asian1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHepatic Insufficiency & Healthy Subjects1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / High Grade Non-Hodgkin's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone B Cell Lymphoma / Small Lymphocytic Lymphoma (SLL)1
1RecruitingTreatmentLeukemias / Malignant Lymphomas1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentRelapsed/Refractory B-cell Malignancies1
2Active Not RecruitingPreventionLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentRelapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Relapsed or Refractory Small Lymphocytic Lymphoma1
2Active Not RecruitingTreatmentRelapsed or Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Leukemia (SLL)1
2RecruitingTreatmentMarginal Zone Lymphoma1
2RecruitingTreatmentRelapsed/Refractory Follicular Non-Hodgkin Lymphoma1
2RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
3Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:44 / Updated on May 21, 2019 12:34